CONMED Corporation
CNMDHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeCONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company carries a $1.48B market cap, placing it firmly in the small-cap category. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries.
Market Cap
$1.48B
Beta
0.91
P/E (TTM)
26.66
P/E (Fwd)
10.31
EPS (TTM)
$1.85
EPS (Fwd)
$4.78
ROE
5.5%
ROA
4.1%
Cash
$37.3M
Total Debt
$834.2M
Free CF
$131.4M
52W Change
-8.6%
Annual Financials
Cash vs Debt
Where CNMD stands vs its 150-day and 200-day moving averages
As of the August 18, 2026 close, CNMD finished 25.19% above its 150-day moving average ($39.34) and 22.91% above its 200-day moving average ($40.07). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CNMD overbought or oversold?
At the August 18, 2026 close, CNMD's RSI(14) was 64.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $37.3M in cash, though total debt stands at $834.2M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $131.4M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 5.5%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.1% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $1.05B (2022) to $1.37B (2025), reflecting a 31% increase over the period.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CNMD.